Oncology Molecular Diagnostics Market Growth: Rising Cancer Screening Demand & Industry Outlook 2026-2034

Market Overview:

According to IMARC Group’s latest research publication, “Oncology Molecular Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034”, The global oncology molecular diagnostics market size reached USD 5.34 Billion in 2025 and is projected to reach USD 15.11 Billion by 2034, exhibiting a CAGR of 11.87% during 2026-2034.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How AI is Reshaping the Future of the Oncology Molecular Diagnostics Market

• AI-driven variant interpretation and digital pathology platforms are scaling rapidly across NGS bioinformatics pipelines, with companies like PathAI, Paige, and Tempus accelerating turnaround times for comprehensive genomic profiling and clinical reporting.
• In March 2026, Illumina announced an expanded collaboration with Labcorp to broaden access to precision oncology testing by applying next-generation sequencing solutions more widely across health systems, promoting equitable cancer biomarker testing and developing new assays to meet unmet needs.
• Multi-cancer early detection tests using blood-based biomarkers and machine learning are advancing toward scaled clinical validation, with GRAIL’s Galleri test anchoring the category while Exact Sciences, Guardant Health, and Freenome continue competing platform development.
• AI-supported tumor board decision-support systems are reducing variant classification time and enabling faster, evidence-backed treatment recommendations, supporting broader adoption of molecular testing across hospital oncology programs.
• Digital PCR platforms enhanced with AI-enabled quantification are enabling superior sensitivity for circulating tumor DNA detection and minimal residual disease monitoring, with QIAGEN’s QIAcuityDx system serving as a key commercial example of this clinical translation.

Download a sample PDF of this report: https://www.imarcgroup.com/oncology-molecular-diagnostics-market/requestsample

Key Trends in the Oncology Molecular Diagnostics Market

• Expansion of Liquid Biopsy and Multi-Cancer Early Detection Platforms: Blood-based liquid biopsy tests that detect cancer-related molecular signals are emerging as promising tools for identifying multiple cancers at earlier stages than current screening methods. Global cancer cases are projected to rise from 20 million in 2022 to 35.3 million by 2050, representing a 76.6% increase, which directly drives the clinical urgency for non-invasive, scalable early detection platforms such as GRAIL Galleri, Guardant Reveal, and Natera Signatera.
• Precision Oncology and Companion Diagnostic Codevelopment: The FDA has approved over 100 targeted oncology therapies paired with companion diagnostics, with biomarker-driven prescribing now the standard of care across breast, lung, colorectal, and adjacent tumor types. Breast cancer leads cancer-type segmentation with a 24.8% share in 2025, underpinned by HER2/neu, BRCA1/2, Oncotype DX, and MammaPrint multi-gene assays that anchor treatment selection decisions.
• Scaling of DNA and NGS Sequencing into Clinical Settings: DNA and next-generation sequencing at 24.5% of the technology mix represents the fastest-growing segment, supported by comprehensive genomic profiling for solid tumors, liquid biopsy applications, and multi-cancer early detection programs. Illumina’s NovaSeq and NextSeq platforms continue to anchor global sequencer infrastructure, with Foundation Medicine, Tempus, and Caris Life Sciences operating large-scale clinical NGS pipelines.
• Tumor-Informed Minimal Residual Disease Monitoring Gains Traction: Tumor-informed MRD assays for colorectal, breast, and lung cancer are scaling through commercial platforms including Natera Signatera and Guardant Reveal. MRD monitoring creates multi-year longitudinal testing opportunities, generating recurring revenue streams alongside upfront comprehensive genomic profiling, and is increasingly referenced in NCCN and ASCO treatment guidelines.
• Digital PCR Entering Mainstream Clinical Oncology Testing: PCR remains the largest technology segment at 31.7% share in 2025, with digital PCR offering superior sensitivity and quantitative precision for circulating tumor DNA, MRD monitoring, and rare variant detection compared with conventional qPCR. QIAGEN’s QIAcuityDx Digital PCR System, launched in September 2024, expanded clinical testing capabilities across North American and European Union markets, marking a key milestone in dPCR’s transition from research to clinical workflows.

The oncology molecular diagnostics market report provides a comprehensive overview of the industry. This analysis is essential for stakeholders aiming to navigate the complexities of the biochar market and capitalize on emerging opportunities. 

Growth Factors in the Oncology Molecular Diagnostics Market

• Rising Global Cancer Burden Driving Sustained Diagnostic Demand: Global cancer incidence is projected to reach 35.3 million cases by 2050, a 76.6% increase from an estimated 20 million cases in 2022. This rising burden drives sustained demand for diagnostic testing across screening, treatment selection, and disease monitoring, with multiple molecular tests required per patient across the entire treatment continuum, significantly expanding total addressable test volumes.
• Reimbursement Expansion Supporting Market Access: Medicare and commercial insurance coverage for comprehensive genomic profiling tests, MRD monitoring, and companion diagnostics continues to expand in the United States. National Comprehensive Cancer Network, ASCO, and ESMO treatment guidelines increasingly recommend molecular testing across solid tumor types, creating a formalized clinical pathway that integrates oncology molecular diagnostics into routine cancer care and accelerates physician adoption.
• North America Leading With 39.4% Market Share: North America accounts for 39.4% of the global market in 2025, supported by the United States as the world’s largest single oncology molecular diagnostics market, comprehensive reimbursement infrastructure for comprehensive genomic profiling and companion diagnostics, and the global concentration of major industry players including Roche, Illumina, Thermo Fisher Scientific, and Hologic.
• Asia Pacific Emerging as the Fastest-Growing Regional Market: Asia Pacific holds a 23.1% share and is on track for the fastest regional growth, supported by rapid clinical adoption across China, Japan, India, and Australia. Expanding insurance coverage frameworks, growing companion diagnostic uptake, and large addressable cancer patient bases in populous markets are collectively driving the regional expansion of oncology molecular diagnostic services and testing infrastructure.
• Strong Venture Capital and Institutional Investment Flowing Into Liquid Biopsy: Liquid biopsy and multi-cancer early detection venture capital remains the most active investment theme globally, with multi-billion-dollar funding rounds supporting Guardant Health, Natera, Exact Sciences, and emerging blood-based cancer detection platforms. AI and bioinformatics platforms attached to molecular diagnostics also represent a substantial software and services investment opportunity, with platforms such as PathAI, Paige, and Tempus commanding significant strategic valuations.

Leading Companies Operating in the Global Oncology Molecular Diagnostics Industry:

• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN
• Hologic, Inc.
• Abbott Laboratories
• Cepheid
• Amadix
• Bio-Rad Laboratories, Inc.
• Natera, Inc.

Oncology Molecular Diagnostics Market Report Segmentation:

Breakup By Technology:

• Polymerase Chain Reaction (PCR)
• In Situ Hybridization
• Chips and Microarrays
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Mass Spectrometry
• DNA and NGS Sequencing
• Transcription Mediated Amplification (TMA)
• Others

PCR accounts for the largest share at 31.7% in 2025, anchored by widespread qPCR and digital PCR adoption across mutation detection, gene expression profiling, MRD monitoring, and companion diagnostic testing due to its lower cost per test, faster turnaround, and broad clinical laboratory installed base.

Breakup By Cancer Type:

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Blood Cancer
• Others

Breast cancer leads with a 24.8% share in 2025, supported by HER2/neu, BRCA1/2 hereditary screening, Oncotype DX, and MammaPrint multi-gene prognostic assays, followed by lung cancer at 21.6%, which reflects high comprehensive genomic profiling adoption for EGFR, ALK, KRAS, and PD-L1 biomarker testing tied to targeted therapy selection.

Breakup By Product:

• Instruments
• Reagents
• Others

Breakup By End-User:

• Hospitals and Clinics
• Reference Laboratories
• Others

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the leading position with a 39.4% share in 2025, driven by the United States as the world’s largest oncology molecular diagnostics market, comprehensive Medicare and commercial insurance reimbursement for comprehensive genomic profiling and companion diagnostics, and FDA leadership in companion diagnostic approvals. Europe holds the second-largest share at 28.2%, supported by national cancer plans and a deep reference laboratory infrastructure across Germany, France, the UK, Italy, and the Nordics.

Recent News and Developments in the Oncology Molecular Diagnostics Market

• March 2026: Illumina announced an expanded collaboration with Labcorp to broaden access to precision oncology testing by applying next-generation sequencing solutions more widely across health systems, promoting equitable cancer biomarker testing, and developing new assays to meet unmet clinical needs.
• May 2026: F. Hoffmann-La Roche announced plans to present new clinical data at the 2026 ASCO Annual Meeting, including subgroup analyses from the Phase III lidERA Breast Cancer trial along with persevERA and evERA findings, supporting giredestrant’s potential to redefine standard of care in ER-positive, HER2-negative breast cancer and reinforcing its companion diagnostics pipeline.
• June 2025: QIAGEN announced the expansion of its oncology diagnostics portfolio through two strategic partnerships with Tracer Biotechnologies and Foresight Diagnostics, advancing the use of minimal residual disease testing in clinical trials and supporting co-development projects for companion diagnostics targeting solid tumor indications.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201-971-6302